StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Equities research analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS - Get Free Report) in a research note issued on Friday. The brokerage set a "strong-buy" rating on the stock.

Separately, Truist Financial lifted their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $23.00.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS traded up $0.22 on Friday, hitting $19.76. The stock had a trading volume of 469,613 shares, compared to its average volume of 371,051. Fresenius Medical Care has a twelve month low of $16.66 and a twelve month high of $22.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. The firm's 50 day moving average price is $20.33 and its 200-day moving average price is $20.18. The company has a market capitalization of $11.60 billion, a price-to-earnings ratio of 20.37, a price-to-earnings-growth ratio of 0.93 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion during the quarter, compared to analysts' expectations of $5.28 billion. On average, equities research analysts predict that Fresenius Medical Care will post 1.52 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company's stock worth $36,000 after purchasing an additional 581 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Fresenius Medical Care by 4.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company's stock valued at $278,000 after acquiring an additional 624 shares during the last quarter. Signaturefd LLC increased its stake in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company's stock valued at $166,000 after acquiring an additional 672 shares during the last quarter. Ritholtz Wealth Management increased its stake in shares of Fresenius Medical Care by 2.5% in the 2nd quarter. Ritholtz Wealth Management now owns 36,901 shares of the company's stock valued at $704,000 after acquiring an additional 895 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company's stock valued at $345,000 after acquiring an additional 1,128 shares during the last quarter. 8.25% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.